News

Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease

The Buck Institute, Insilico Medicine, and Juvenescence Ltd have formed Napa Therapeutics to develop drugs against a novel aging-related target. Napa Therapeutics is based on groundbreaking research in NAD metabolism conducted in the lab of Eric Verdin, MD, President & CEO of the Buck Institute

Continue Reading
Juvenescence Acquires Major Interest In AgeX

Juvenescence Acquires Major Interest In AgeX

· BioTime to receive $21.6 million in cash and $21.6 million in a convertible/redeemable note for 14.4 million shares of AgeX Therapeutics · Creates alignment between AgeX Therapeutics and Juvenescence Limited to drive leadership in the field of ageing

Continue Reading
Juvenescence Establishes Joint Venture With Antoxerene To Evaluate Senolytics

Juvenescence Establishes Joint Venture With Antoxerene To Evaluate Senolytics

Juvenescence and Antoxerene, a subsidiary of Ichor Therapeutics, have created Fox Bio, Inc. a joint venture to investigate their portfolio of senolytic drugs Initial investment of $3,000,000, with a second milestone payment of $7,000,000

Continue Reading